<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> (also referred to as <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>) is a drug that has recently been approved by the Food and Drug Administration (FDA) for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanism of action is believed to be the blocking of DNA methylation and thereby reactivating silenced genes involved in harnessing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>When analyzing reactivation of genes involved in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), we discovered that <z:chebi fb="0" ids="50131">decitabine</z:chebi> also sensitizes <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells by inducing DNA damage </plain></SENT>
<SENT sid="3" pm="."><plain>This sensitization is grossly augmented by the MYC oncogene, which is overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, and occurs in cells lacking a functional p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor pathway </plain></SENT>
<SENT sid="4" pm="."><plain>In p53-deficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells and p53(-/-) mouse embryo fibroblasts, Myc overrides a transient G2-block exerted by <z:chebi fb="0" ids="50131">decitabine</z:chebi> via activation of Chk1 </plain></SENT>
<SENT sid="5" pm="."><plain>This triggers <z:mp ids='MP_0004024'>aneuploidy</z:mp> and cell <z:hpo ids='HP_0011420'>death</z:hpo> that correlates with, but can occur in the absence of, Epstein-Barr virus (EBV) reactivation, caspase activation, and/or expression of the <z:chebi fb="0" ids="30153">BH3</z:chebi>-only protein Puma </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo modeling of Myc-induced <z:hpo ids='HP_0002665'>lymphoma</z:hpo> suggests that <z:chebi fb="0" ids="50131">decitabine</z:chebi> constitutes a potential new drug against <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that would selectively sensitize <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells but spare <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
</text></document>